Validating the Disruption of Proliferating Cell Nuclear Antigen Interactions in the Development of Targeted Cancer Therapeutics.

Validating the Disruption of Proliferating Cell Nuclear Antigen Interactions in the Development of Targeted Cancer Therapeutics.

Cancer Biol Ther. 2016 Feb 18;:0

Authors: Smith SJ, Hickey RJ, Malkas LH

Abstract
Human DNA replication and repair is a highly coordinated process involving the specifically timed actions of numerous proteins and enzymes. Many of these proteins require interaction with proliferating cell nuclear antigen (PCNA) for activation within the process. The interdomain connector loop (IDCL) of PCNA provides a docking site for many of those proteins, suggesting that this region is critically important in the regulation of cellular function. Previous work in this laboratory has demonstrated that a peptide mimicking a specific region of the IDCL (caPeptide) has the ability to disrupt key protein-protein interactions between PCNA and its binding partners, thereby inhibiting DNA replication within the cells. In this study, we confirm the ability of the caPeptide to disrupt DNA replication function using both intact cell and in vitro DNA replication assays. Further, we were able to demonstrate that treatment with caPeptide results in a decrease of polymerase δ activity that correlates with the observed decrease in DNA replication. We have also successfully developed a surface plasmon resonance (SPR) assay to validate the disruption of the PCNA-pol δ interaction with caPeptide.

PMID: 26889573 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/1Q57IUx
via IFTTT